Roquefort Therapeutics PLC
LSE:ROQ
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.15
3.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
R
|
Roquefort Therapeutics PLC
LSE:ROQ
|
1.9m GBP |
Loading...
|
|
| US |
|
SoFi Technologies Inc
NASDAQ:SOFI
|
29.5B USD |
Loading...
|
|
| MC |
|
HAL Trust
AEX:HAL
|
14B EUR |
Loading...
|
|
| US |
|
Annaly Capital Management Inc
NYSE:NLY
|
16.3B USD |
Loading...
|
|
| US |
|
WP Carey Inc
NYSE:WPC
|
15.1B USD |
Loading...
|
|
| US |
|
Ares Capital Corp
NASDAQ:ARCC
|
14.5B USD |
Loading...
|
|
| US |
|
AltC Acquisition Corp
NYSE:OKLO
|
13.5B USD |
Loading...
|
|
| BE |
|
Sofina SA
XBRU:SOF
|
9.1B EUR |
Loading...
|
|
| US |
|
Starwood Property Trust Inc
NYSE:STWD
|
6.7B USD |
Loading...
|
|
| US |
|
Main Street Capital Corp
NYSE:MAIN
|
5.8B USD |
Loading...
|
|
| KY |
J
|
JATT Acquisition Corp
F:1GU
|
4.6B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Roquefort Therapeutics PLC
Glance View
Roquefort Therapeutics plc operates as an investment company. The firm is developing products through the pre-clinical phase. The firm operates through its subsidiary Lyramid Pty Ltd (Lyramid). Lyramid is a pre-clinical biotechnology company focused on developing first-in-class Midkine inhibiting ribonucleic acid (RNA) therapeutic drugs for the treatment of cancer, chronic inflammatory, and autoimmune disorders, as well as lung diseases such as COVID-19. Lyramid has identified the therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid also intends to develop its oligonucleotide, and potentially antibody, drugs through preclinical and early clinical development.